Sign up for ICER's Weekly View Newsletter

Programming note: The Weekly View will be back in your inbox on July 10th. Have a great July 4th weekend!

 

Weekly View


June 26, 2026

From the desk of Priya Ranade

Good morning, everyone.

From ICER’s President and CEO Sarah K. Emond, MPP:

 

This week, ICER hosted a public meeting on the clinical and cost effectiveness of Covid-19 vaccines. A special thank you to all the organizations that participated in yesterday’s meeting, including: the National Health Council, AARP, AHIP, the American Pharmacists Association, the Patient Advocate Foundation, and the New York State Department of Health. We also want to thank the New England CEPAC, an independent committee comprised of experts across health policy, health economics, patient advocacy, evidence-based medicine, and clinical research, for a fruitful discussion around the findings of the ICER report.

 

Coming out of the ICER public meeting, many stakeholders agreed that the current confusion around vaccine policy is alarming. Our health care system works best when public health officials have access to independent experts who can evaluate the data on the effectiveness of medical interventions, like vaccines, so that those officials can make clear recommendations for the public. For 20 years, ICER has provided evidence-based analyses on how well therapies work for patients. And for 20 years, policymakers have been using our public and transparent analyses to inform recommendations that support both individual and public health.

 

If you missed the June 25th public meeting, a recording of the meeting will be available for viewing next week on ICER’s website. The Final Evidence Report will be published on July 28th and include a full summary of the public meeting and resulting policy recommendations.

Let's see what else happened this week...

 
Pharmaceutical News

MUST READS


Nation's health care tab hit $5.7 trillion last year

Axios

Growing demand for medical care and high-cost drugs helped drive up national health spending 7.3% last year, to $5.7 trillion, according to new projections federal actuaries released on Wednesday. It marked the third consecutive year that health spending rose above 7% — a trend that's likely to continue this year and intensify affordability concerns.

IRA's $2,000 out-of-pocket cap helped Medicare patients access expensive drugs, study finds

Endpoints News

Medication usage, particularly for the most expensive drugs, increased shortly after the Medicare annual out-of-pocket cost cap took effect in January 2025, a study published in JAMA Health Forum on Thursday found.


The results suggest the cap worked as intended to increase patients’ access to medicines, according to the authors, who are physicians in Harvard Medical School’s Program on Regulation, Therapeutics, and Law. They used data from Symphony Health’s Metys pharmacy database to evaluate how the $2,000 annual cap affected quarterly prescription fills for drugs reimbursed by Medicare when compared with commercial insurance from 2022 to 2025.

US prices for new drugs fell in 2025 as fewer costly gene therapies were launched

Reuters

Launch prices for prescription medicines approved by U.S. regulators in 2025 fell from the previous year, but remained high at a median of $216,000 due to expensive drugs for rare diseases, a new analysis shows. In 2024, the median annual list price of a new drug was over $370,000, up from $300,000 in 2023 and $222,000 in 2022.


ICER is currently working on a second annual Launch Price and Access Report, which will be available in October 2026.

Florida launches probe into CVS for alleged anticompetitive pharmacy practices

BioPharma Dive

Florida is launching an investigation into CVS Health and its pharmacy benefit manager Caremark for allegedly driving up the cost of medications.


Critics argue the biggest PBMs — CVS’ Caremark, UnitedHealth’s Optum Rx and Cigna’s Express Scripts, which jointly control 80% of all U.S. prescriptions — operate large, integrated health care businesses and use that leverage to profit. They say the PBMs steer patients toward their own pharmacies and impose arbitrary or unfair contracts on smaller pharmacies, driving independent operators out of business. 

Covid-19 vaccine study that was blocked from CDC journal is published elsewhere

The Associated Press

A study on COVID-19 vaccine effectiveness has finally been published after being blocked from a government health journal. The vaccine was found to be about 55% effective against Covid-19-associated hospitalizations, and reduced Covid-19-related trips to emergency departments and urgent care clinics by 50%, according to the study published Tuesday by JAMA Network Open.

OTHER HEADLINES

 

Join ICER!

 

Want to work for a fast-paced, mission-driven organization? Look no further! ICER is looking to expand our team:



 

Key Upcoming Dates

 
  • 7/27: Parkinson's Disease -- Draft Evidence Report
  • 7/28: Covid-19 -- Final Evidence Report

Learn more about ICER’s ongoing and recently completed reports:

Email info@icer.org for more information.

When you make a gift to ICER, you help keep ICER independent.  

 
 
 
 
 
LinkedIn Share This Email